Heart failure and anti tumornecrosis factor-alpha in systemic chronic inflammatory diseases.

Mario Cottone, Mario Cottone, Emanuele Sinagra, Claudia Romano, Giovanni Perricone, Claudia Romano

Risultato della ricerca: Article

31 Citazioni (Scopus)

Abstract

Tumor necrosis factor alpha (TNF-alpha) antagonists have emerged as an effective therapy for patients with diseases as Crohn's disease, rheumatoid arthritis, and other chronic systemic inflammatory diseases. In the last years, there has been a growing interest in the role that inflammatory cytokines, which sustain the pathogenesis of these diseases, plays in regulating cardiac structure and function, particularly in the progression of chronic heart failure. In fact there is an increase of anti-TNF alpha levels in advanced heart failure but the treatment with anti-TNF alpha has been shown to worsen the prognosis of heart failure in randomized controlled trials. Patients with rheumatoid arthritis have an increased risk for cardiovascular disease and anti-TNF alpha therapy seems to be beneficial on the risk of cardiovascular disease. In Crohn's disease the increased risk of cardiovascular disease is controversial and therefore it is impossible to demonstrate an effect in reduction of the risk; however, heart failure in patients treated with anti-TNF alpha, despite in a small proportion, has been observed. On the basis of this observation, anti-TNF alpha therapy is contraindicated in patients with Crohn's disease and III-IV New York Heart Association heart failure class.
Lingua originaleEnglish
pagine (da-a)385-392
Numero di pagine8
RivistaEuropean Journal of Internal Medicine
Volume24
Stato di pubblicazionePublished - 2013

Fingerprint

Chronic Disease
Heart Failure
Tumor Necrosis Factor-alpha
Crohn Disease
Cardiovascular Diseases
Rheumatoid Arthritis
Risk Reduction Behavior
Therapeutics
Randomized Controlled Trials
Cytokines

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cita questo

Heart failure and anti tumornecrosis factor-alpha in systemic chronic inflammatory diseases. / Cottone, Mario; Cottone, Mario; Sinagra, Emanuele; Romano, Claudia; Perricone, Giovanni; Romano, Claudia.

In: European Journal of Internal Medicine, Vol. 24, 2013, pag. 385-392.

Risultato della ricerca: Article

Cottone, M, Cottone, M, Sinagra, E, Romano, C, Perricone, G & Romano, C 2013, 'Heart failure and anti tumornecrosis factor-alpha in systemic chronic inflammatory diseases.', European Journal of Internal Medicine, vol. 24, pagg. 385-392.
Cottone, Mario ; Cottone, Mario ; Sinagra, Emanuele ; Romano, Claudia ; Perricone, Giovanni ; Romano, Claudia. / Heart failure and anti tumornecrosis factor-alpha in systemic chronic inflammatory diseases. In: European Journal of Internal Medicine. 2013 ; Vol. 24. pagg. 385-392.
@article{11ae2c11968c4a5ea82733d6e7b635b2,
title = "Heart failure and anti tumornecrosis factor-alpha in systemic chronic inflammatory diseases.",
abstract = "Tumor necrosis factor alpha (TNF-alpha) antagonists have emerged as an effective therapy for patients with diseases as Crohn's disease, rheumatoid arthritis, and other chronic systemic inflammatory diseases. In the last years, there has been a growing interest in the role that inflammatory cytokines, which sustain the pathogenesis of these diseases, plays in regulating cardiac structure and function, particularly in the progression of chronic heart failure. In fact there is an increase of anti-TNF alpha levels in advanced heart failure but the treatment with anti-TNF alpha has been shown to worsen the prognosis of heart failure in randomized controlled trials. Patients with rheumatoid arthritis have an increased risk for cardiovascular disease and anti-TNF alpha therapy seems to be beneficial on the risk of cardiovascular disease. In Crohn's disease the increased risk of cardiovascular disease is controversial and therefore it is impossible to demonstrate an effect in reduction of the risk; however, heart failure in patients treated with anti-TNF alpha, despite in a small proportion, has been observed. On the basis of this observation, anti-TNF alpha therapy is contraindicated in patients with Crohn's disease and III-IV New York Heart Association heart failure class.",
author = "Mario Cottone and Mario Cottone and Emanuele Sinagra and Claudia Romano and Giovanni Perricone and Claudia Romano",
year = "2013",
language = "English",
volume = "24",
pages = "385--392",
journal = "European Journal of Internal Medicine",
issn = "0953-6205",
publisher = "Elsevier",

}

TY - JOUR

T1 - Heart failure and anti tumornecrosis factor-alpha in systemic chronic inflammatory diseases.

AU - Cottone, Mario

AU - Cottone, Mario

AU - Sinagra, Emanuele

AU - Romano, Claudia

AU - Perricone, Giovanni

AU - Romano, Claudia

PY - 2013

Y1 - 2013

N2 - Tumor necrosis factor alpha (TNF-alpha) antagonists have emerged as an effective therapy for patients with diseases as Crohn's disease, rheumatoid arthritis, and other chronic systemic inflammatory diseases. In the last years, there has been a growing interest in the role that inflammatory cytokines, which sustain the pathogenesis of these diseases, plays in regulating cardiac structure and function, particularly in the progression of chronic heart failure. In fact there is an increase of anti-TNF alpha levels in advanced heart failure but the treatment with anti-TNF alpha has been shown to worsen the prognosis of heart failure in randomized controlled trials. Patients with rheumatoid arthritis have an increased risk for cardiovascular disease and anti-TNF alpha therapy seems to be beneficial on the risk of cardiovascular disease. In Crohn's disease the increased risk of cardiovascular disease is controversial and therefore it is impossible to demonstrate an effect in reduction of the risk; however, heart failure in patients treated with anti-TNF alpha, despite in a small proportion, has been observed. On the basis of this observation, anti-TNF alpha therapy is contraindicated in patients with Crohn's disease and III-IV New York Heart Association heart failure class.

AB - Tumor necrosis factor alpha (TNF-alpha) antagonists have emerged as an effective therapy for patients with diseases as Crohn's disease, rheumatoid arthritis, and other chronic systemic inflammatory diseases. In the last years, there has been a growing interest in the role that inflammatory cytokines, which sustain the pathogenesis of these diseases, plays in regulating cardiac structure and function, particularly in the progression of chronic heart failure. In fact there is an increase of anti-TNF alpha levels in advanced heart failure but the treatment with anti-TNF alpha has been shown to worsen the prognosis of heart failure in randomized controlled trials. Patients with rheumatoid arthritis have an increased risk for cardiovascular disease and anti-TNF alpha therapy seems to be beneficial on the risk of cardiovascular disease. In Crohn's disease the increased risk of cardiovascular disease is controversial and therefore it is impossible to demonstrate an effect in reduction of the risk; however, heart failure in patients treated with anti-TNF alpha, despite in a small proportion, has been observed. On the basis of this observation, anti-TNF alpha therapy is contraindicated in patients with Crohn's disease and III-IV New York Heart Association heart failure class.

UR - http://hdl.handle.net/10447/74782

M3 - Article

VL - 24

SP - 385

EP - 392

JO - European Journal of Internal Medicine

JF - European Journal of Internal Medicine

SN - 0953-6205

ER -